



NEWS RELEASE

June 16, 2005

MDS Nordion announces commercial availability of copper-64 *Radioisotope shows potential for use in molecular imaging, drug development and radiotherapy*

Ottawa, Canada - MDS Nordion today announced the commercial availability of copper-64 (Cu-64). Cu-64 is principally used as a positron emission tomography (PET) imaging isotope that provides physicians with higher resolution images to better diagnose and monitor disease. Cu-64 is advantageous in that it is a “long-lived” PET isotope with a half-life of 12.7 hours and can be distributed commercially, eliminating the need for users to have an on-site isotope production facility. In addition, there is growing interest in the use of Cu-64 in molecular imaging and biodistribution studies as part of the drug development process as well as possible therapeutic applications for the treatment of disease.

“MDS Nordion has continued to play an important role in advancing medical research in molecular imaging and therapy. The commercial availability of a radionuclide, like Cu-64, will facilitate investigations of innovative diagnostic and therapeutic importance ultimately leading to better diagnosis and treatment of disease,” said **Dr. Mathew L. Thakur, President, Society of Nuclear Medicine and Director, Radiopharmaceutical Research and Professor of Radiology & Radiation Oncology at Thomas Jefferson University** in Philadelphia, PA.

MDS Nordion’s technical, operational and market expertise means that the nuclear medicine, biotechnology and pharmaceutical communities now have a dependable and secure supply of Cu-64. In addition to strong technical and scientific expertise, the company provides consistent product quality and responsive customer service.

“MDS Nordion is committed to advancing the growth of nuclear medicine by providing products and services that support innovation and research,” said **Iain Trevena, Senior Vice President, Nuclear Medicine at MDS Nordion**. “Researchers now have another tool with which they can explore new treatments for cancer and other diseases. The use of Cu-64 to improve the testing of pharmaceuticals while in development is also being explored by biotechnology and drug development companies.”

Building on its experience as a global leader in radioisotope supply and radiopharmaceutical manufacturing, MDS Nordion is expanding its range of products and services to support innovation and optimize the drug discovery and development process. By offering integrated services to support the discovery and pre-clinical development of novel

diagnostic and therapeutic radiopharmaceuticals, as well as molecular imaging applications, MDS Nordion is helping biotechnology and pharmaceutical companies to bring products to market faster.

About MDS Nordion

MDS Nordion (www.mds.nordion.com) is a world leader in radioisotopes, radiation and related technologies. MDS Nordion is part of MDS Inc. (TSX:MDS; NYSE:MDZ). MDS Inc. has more than 9,000 highly skilled people in 27 countries. We provide a diverse range of superior products and services to increase our customers' speed, precision and productivity in the drug development and disease diagnosis processes. We are a global, values-driven health and life sciences company, recognized for our reliability and collaborative relationships as we help create better outcomes in the treatment of disease. Find out more at www.mdsintl.com or by calling 1-888-MDS-7222, 24 hours a day.

-30-

For more information contact:

Olivia Nixon
Media Relations, MDS Nordion
Tel: (613) 592-3400 ext. 2832
E-mail: onixon@mds.nordion.com